Stakeholder Consultation Workshop on the Perceived Value of Thermostable Vaccines to Relieve Program Barriers: A Case Study from Côte d’Ivoire

Uloženo v:
Podrobná bibliografie
Vydáno v:Vaccines vol. 12, no. 12 (2024), p. 1414
Hlavní autor: Kahn, Anna-Lea
Další autoři: Spasenoska, Dijana, Kouadio Daniel Ekra, Coulibaly, Soplé Ruth, Yao, Kossia, Kouadio, Sié Kabran, Sar, Aminatou, Robertson, Joanie
Vydáno:
MDPI AG
Témata:
On-line přístup:Citation/Abstract
Full Text + Graphics
Full Text - PDF
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

MARC

LEADER 00000nab a2200000uu 4500
001 3149767449
003 UK-CbPIL
022 |a 2076-393X 
024 7 |a 10.3390/vaccines12121414  |2 doi 
035 |a 3149767449 
045 2 |b d20240101  |b d20241231 
084 |a 231639  |2 nlm 
100 1 |a Kahn, Anna-Lea  |u World Health Organization (WHO) Headquarters, Avenue Appia 20, 1211 Geneva, Switzerland; Swiss Centre for International Health, Swiss Tropical and Public Health Institute, 4123 Basel, Switzerland; Faculty of Medicine, University of Basel, 4056 Basel, Switzerland 
245 1 |a Stakeholder Consultation Workshop on the Perceived Value of Thermostable Vaccines to Relieve Program Barriers: A Case Study from Côte d’Ivoire 
260 |b MDPI AG  |c 2024 
513 |a Journal Article 
520 3 |a Background: Persistent inequities in access to vaccinations pose challenges for immunization programs worldwide. Innovations facilitating vaccine delivery, such as leveraging vaccine thermostability through a Controlled Temperature Chain (CTC), have emerged as a potential solution to increase coverage in low- and middle-income countries (LMICs) countries such as Côte d’Ivoire, reducing dependence on the cold chain and improving vaccine delivery efficiency. However, the added value of thermostable vaccines and their integration into national immunization programs is under-recognized by stakeholders. This consultation aimed to convene key immunization stakeholders in Côte d’Ivoire in order to examine their perceptions regarding the value of vaccine thermostability to address barriers to outreach and equity in immunization programs. Methods: A novel workshop model involving structured group discussions was used to document the viewpoints of national stakeholders representing different areas of the immunization program. They prioritized barriers undermining coverage and equity in their country and explored the potential impact of CTC on the immunization program in the context of thermostable vaccines. The vaccines discussed were for Hepatitis B, Human Papillomavirus, and Meningitis. Results: The workshop outcomes highlighted the context and vaccine-specific variation of the importance of certain barriers, emphasizing the need for tailored strategies. The barriers considered most likely to be alleviated by vaccine thermostability were under the categories of human resource management, vaccine supply and logistics, and services delivery. The least relevant category of barriers concerned demand generation. Conclusions: The consultation provided valuable insights into stakeholder perspectives, priorities, and conditions for the effective integration of thermostable vaccines, informing future product development and policy decisions to optimize vaccine delivery and address immunization challenges in LMICs. 
653 |a Innovations 
653 |a Hepatitis B 
653 |a Human papillomavirus 
653 |a Cold 
653 |a Product development 
653 |a Thermal stability 
653 |a Vaccines 
653 |a Meningitis 
653 |a Workshops 
653 |a Immunization 
653 |a Human resource management 
653 |a Underserved populations 
653 |a Social 
653 |a Economic 
700 1 |a Spasenoska, Dijana  |u World Health Organization (WHO) Headquarters, Avenue Appia 20, 1211 Geneva, Switzerland; Department of Social Policy, London School of Economics and Political Science, London WC2A 2AE, UK 
700 1 |a Kouadio Daniel Ekra  |u Expanded Program on Immunization (EPI), Ministry of Health, Abidjan, Côte d’Ivoire 
700 1 |a Coulibaly, Soplé Ruth  |u Expanded Program on Immunization (EPI), Ministry of Health, Abidjan, Côte d’Ivoire 
700 1 |a Yao, Kossia  |u Expanded Program on Immunization (EPI), Ministry of Health, Abidjan, Côte d’Ivoire 
700 1 |a Kouadio, Sié Kabran  |u World Health Organization (WHO) Country Office, Abidjan, Côte d’Ivoire 
700 1 |a Sar, Aminatou  |u United Nations Sustainable Development Group, Cotonou 01-3621, Benin; PATH-Senegal, Dakar BP 15115, Senegal 
700 1 |a Robertson, Joanie  |u PATH-Headquarters, Seattle, WA 98121, USA; <email>jrobertson@path.org</email> 
773 0 |t Vaccines  |g vol. 12, no. 12 (2024), p. 1414 
786 0 |d ProQuest  |t Biological Science Database 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3149767449/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch 
856 4 0 |3 Full Text + Graphics  |u https://www.proquest.com/docview/3149767449/fulltextwithgraphics/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3149767449/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch